Condition category
Musculoskeletal Diseases
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting

Plain English Summary

Background and study aims
In autoimmune diseases such as systemic lupus erythematosus (SLE), the immune system has lost the ability to discriminate between body-own ('self') and foreign proteins. In consequence, antibodies are generated to attack 'self'-proteins and form immune complexes which continuously activate the immune system through binding to specific immune cells in the body. As a result, the activated immune system can lead to severe organ damage, including the kidney. This study investigates a new treatment for preventing and/ or ameliorating SLE in patients with or without a history of lupus nephritis ((prolonged inflammation of kidneys). Previous investigations in SLE animal studies suggest that the drug SM101 competes with the immune complex binding and has the potential to prevent organ damage caused by the activated immune system. The aim of the SMILE clinical trial in SLE is to investigate the safety and efficacy of SM101 in the treatment of SLE patients with or without a history of lupus nephritis and a SELENA-SLEDAI score of ≥ 6.

Who can participate?
SLE patients with or without a history of lupus nephritis and a SELENA-SLEDAI score of ≥ 6.

What does the study involve?
The study includes 10 visits for non-pharmacokinetic (PK) patients and 13 visits for PK patients. There is a 3 weeks screening period, a 4 weeks treatment and a 5 months follow-up period. SLE patients with or without a history of lupus nephritis, a SELENA-SLEDAI score of ≥ 6, serological active (abnormal dsDNA or C3 titres) with stable immunosuppressive therapy may be eligible for the study.

What are the possible benefits and risks of participating?
Previous studies suggest that SM101 appears to be generally well tolerated and safe. However some patients may experience some adverse reactions which have not been reported so far. The side effects may be a minor inconvenience or could be severe. Patients will be watched closely for any side effects, and the drug will be stopped if serious side effects develop.

Where is the study run from?
Thirty clinical trial sites for the SMILE study are located in Australia, Belgium, Czech Republic, France, Germany, Italy, Netherlands, Poland, Spain and UK.

When is the study starting and how long is it expected to run for?
The first enrolment of patients is planned for August 2011 with a recruitment period of 14 months until October 2012.

Who is funding the study?
SuppreMol GmbH (Germany)

Who is the main contact?
Sascha Tillmanns, Medical Director, SuppreMol GmbH

Trial website

Contact information



Primary contact

Mr Sascha Tillmanns


Contact details

SuppreMol GmbH
Am Klopferspitz 19

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

Phase IIa, 2:2:1 randomised, double-blind, placebo-controlled, parallel group, multi-centre clinical trial to investigate the safety, efficacy and pharmacokinetics of recombinant human soluble Fc-gamma receptor IIb (SM101) for intravenous application in the treatment of systemic lupus erythematosus (SLE) patients with or without a history of lupus nephritis



Study hypothesis

The human soluble Fcγ receptor SM101 competes with the binding of systemic lupus erythematosus (SLE)-specific immune complexes to effector cells and therefore interrupts the immunological cascade leading to inflammation and organ damage.

Ethics approval

Approval pending as of 30/06/2011

Study design

Phase IIa 2:2:1 randomised double-blind placebo-controlled parallel group multi-centre proof-of-concept clinical trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details below to request a patient information sheet


Systemic lupus erythematosus patients with or without a history of lupus nephritis


Three treatment arms, two interventions groups and a placebo in parallel fashion:
1. Intervention group 1: 6 mg/kg/week SM101 for 4 weeks
2. Intervention group 2: 12 mg/kg/week SM101 for 4 weeks
3. Placebo

Intervention type



Phase II

Drug names


Primary outcome measures

Incidence of adverse events (AEs) during the study period according to Common Terminology Criteria for Adverse Events (CTCAE)

Secondary outcome measures

1. Physical examination (screening)
2. Vital signs (screening, treatment, follow-up)
3. Body temperature (screening, treatment, follow-up)
4. Body weight (screening, treatment)
5. Electrocardiogram (ECG) (screening, treatment, follow-up)
6. Safety laboratory assessments (screening, treatment, follow-up)
7. Anti-drug antibody (ADA) (treatment, follow-up)
8. AE recording (continuously)
9. Overall and renal disease score assessments, proteinuria, urine sediment, glomerular filtration rate (GFR), biological markers, anti-double-stranded DNA (dsDNA), anti-C1q, C3, C4, urinary neutrophil gelatinase-associated lipocalin (uNGAL) (continuously)
10. Use of rescue medication (all during screening, treatment, follow-up)

Overall trial start date


Overall trial end date


Reason abandoned


Participant inclusion criteria

1. Patient has provided written informed consent prior to any study-related procedure
2. Male or female adult patients aged 18 years or older
3. Diagnosis of SLE meeting at least four revised main classification criteria of the American College of Rheumatology (ACR) with or without a history of glomerulonephritis
4. Clinically active patients with a SLE Disease Activity Index (SELENA-SLEDAI) score of ≥ 6
5. Patients with a current serological active status (anti-dsDNA or C3)
6. Concurrent maintenance immunosuppressant SLE treatment (if any) with prednisone alone or in combination with either azathioprine or mycophenolate mofetil
7. Adequate liver function

Participant type


Age group




Target number of participants

50 patients

Participant exclusion criteria

1. Patient is intended to receive immunosuppressive SLE treatment other than listed in the inclusion criteria
2. Patients with proteinuria > 3.5 g/day at baseline or glomerular filtration rate (GFR) < 60 mL/min/1.73 m2
3. Patients with active SLE neurological disorders
4. Patients with an acute British Isles Lupus Assessment Group (BILAG) score defined as >= 1 BILAG A score or >= 2 BILAG B scores
5. History of class VI glomerulonephritis
6. Patients with non-lupus related renal disease such as microthrombotic disease associated with antiphospholipid syndrome
7. Patients with other acute infections
8. Patient received any B cell depleting therapy

Recruitment start date


Recruitment end date



Countries of recruitment

Australia, Belgium, Czech Republic, France, Germany, Italy, Poland, Spain, United Kingdom

Trial participating centre

SuppreMol GmbH

Sponsor information


SuppreMol GmbH (Germany)

Sponsor details

Am Klopferspitz 19

Sponsor type




Funder type


Funder name

SuppreMol GmbH (Germany)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes